Raise closed, search for fresh raises on Seedstage

Montgomery, TX

Advancing development of gene therapy solutions to treat heart and kidney diseases in pets.

• Innovative approach: Utilizing non-viral, transient gene therapy to drive regenerative healing.
• Clinical validation: Demonstrated safety and efficacy signals in human Phase 2 studies.
• Strategic market entry: Targeting companion animal health market for near-term commercialization.
• Strong leadership: Led by experienced biotech and regenerative medicine executives.
• Scalable platform: Offers an off-the-shelf, affordable alternative to cell-based therapies.

Foment Bio is raising funds to advance its development of a novel non-viral transient gene therapy platform that stimulates the body’s natural ability to heal. The company is initially targeting the companion animal health market, aiming to treat heart failure and chronic kidney disease in pets by inducing in vivo exosome production. Their approach leverages plasmid constructs to stimulate natural regenerative processes without the complexity and cost associated with traditional cell-based or viral therapies. By offering an off-the-shelf, scalable, and repeatable solution, Foment Bio plans to provide veterinarians and pet owners with an innovative alternative to current symptom-management options.

The funds raised will support preclinical and clinical development activities, including a pilot dog study for their lead therapeutic candidate. Foment Bio’s near-term commercialization strategy in the veterinary sector is designed to generate early revenue streams that can fund further research and development efforts targeting human health applications. With an experienced leadership team, extensive IP portfolio, and early clinical validation demonstrating safety and signals of efficacy, Foment Bio seeks to address major unmet needs in both veterinary and human cardiometabolic health markets by offering a novel therapeutic option that addresses the root causes of disease rather than just managing symptoms.

Company Info

Foment Bio is pioneering non-viral gene therapy to drive natural tissue repair, starting with heart and kidney diseases in companion animals.

Foment Bio is a biopharmaceutical company developing a novel, non-viral, transient gene therapy platform that induces regenerative healing by stimulating exosome production directly within the body. Their injectable, off-the-shelf solution aims to treat cardiometabolic dysfunction, including heart failure and chronic kidney disease, first targeting the $27B+ companion animal health market for near-term commercialization. Building on the safety and observed efficacy signals from over 200 patients treated in Phase 2 FDA studies, Foment’s scalable and affordable approach offers a promising alternative to traditional cell or viral gene therapies.

Led by CEO Ben Chlebina and Dr. Marc Penn, the founding team brings deep experience in regenerative medicine, clinical translation, and biotech commercialization. The company’s platform technology targets both veterinary and human health markets, addressing multi-billion-dollar opportunities in cardiometabolic disease and regenerative medicine.